文献速递肾癌与肾肿瘤

活检细胞周期增殖评分预测局限性肾细胞癌不良手术病理

Biopsy Cell Cycle Proliferation Score Predicts Adverse Surgical Pathology in Localized Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2020-09-14

这项回顾性多机构队列研究纳入202例先行肾肿块活检后手术的局限性肾细胞癌患者,评估活检标本细胞周期增殖(CCP)评分预测不良手术病理(3-4级、pT分期≥3、手术时转移或II型乳头状)的能力。98例(49%)存在不良病理,CCP评分作为二分类变量(CCP>0,OR 2.44,p=0.02)和连续变量(每增加1单位OR 1.72,p=0.04)均与不良病理显著相关,AUC从基线模型0.73提升至0.75和0.76。

要点

  • 活检CCP评分可独立预测局限性肾细胞癌不良手术病理。
  • 加入CCP评分后模型区分度AUC由0.73升至0.75-0.76。
  • 活检CCP模型在配对亚组中优于肾切除标本模型(AUC 0.78 vs 0.75)。

核心结论

  • 活检标本CCP评分与局限性肾细胞癌不良手术病理显著相关,可提升基线模型的区分能力。

研究设计与样本

  • 回顾性多机构队列研究,纳入202例先行肾肿块活检后接受手术的局限性肾细胞癌患者。

主要发现

  • 202例中98例(49%)存在不良手术病理。
  • CCP评分>0与不良病理相关(OR 2.44,p=0.02),作为连续变量每增加1单位OR 1.72(p=0.04)。
  • 基线模型AUC 0.73,加入CCP评分后AUC为0.75和0.76。
  • 在具有肾切除CCP评分的67例亚组中,活检模型AUC 0.78优于肾切除模型0.75。

临床怎么用

  • 活检CCP评分可作为辅助工具,帮助识别适合主动监测的局限性肾细胞癌患者。

局限性

  • 回顾性设计,需前瞻性评估以确认临床有效性及在主动监测适用人群中的潜在效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Active surveillance (AS) is an accepted management strategy for some patients with renal cell carcinoma, but limited tools are available to identify optimal AS candidates. While renal mass biopsy provides diagnostic information, risk stratification based on biopsy is limited. In a retrospective, multi-institutional cohort that underwent renal mass biopsy followed by surgery, we assessed the ability of the cell cycle proliferation (CCP) score from clinical biopsy specimens to predict adverse surgical pathology (ie, grade 3-4, pT stage ≥3, metastasis at surgery, or papillary type II). Of 202 patients, 98 (49%) had adverse surgical pathology. When added to a baseline model including age, sex, race, lesion size, biopsy grade, and histology, CCP score was significantly associated with adverse pathology when modeled as a binary (odds ratio [OR]: 2.44 for CCP score >0, p = 0.02) and a continuous (OR: 1.72 per one unit increase, p = 0.04) variable. Discriminative performance measured by the area under the curve (AUC) improved from 0.73 in the baseline model to 0.75 and 0.76 in models including the CCP score. In the subgroup of patients with nephrectomy CCP score available (n = 67), the biopsy-based model outperformed the nephrectomy-based model (AUC 0.78 vs 0.75). These data support prospective assessment of biopsy CCP score to confirm clinical validity and assess potential utility in AS-eligible patients. PATIENT SUMMARY: In patients with localized renal cell carcinoma who underwent renal mass biopsy followed by surgery, the cell cycle proliferation score from clinical biopsy specimens could predict adverse surgical pathology.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Tosoian JJ, Feldman AS, Abbott MR, et al. Biopsy Cell Cycle Proliferation Score Predicts Adverse Surgical Pathology in Localized Renal Cell Carcinoma. Eur Urol. 2020. PMID: 32943262. doi:10.1016/j.eururo.2020.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。